Insuman Rapid 100 IU/ml solution for injection in a cartridge
- Name:
Insuman Rapid 100 IU/ml solution for injection in a cartridge
- Company:
SANOFI
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 07/05/19
(Click to Download)Click on this link to Download PDF directly
SANOFI
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 7 May 2019 PIL
Reasons for updating
- Change to section 3 - how to take/use
Updated on 26 April 2019
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.6 - Special precautions for disposal and other handling
Free text change information supplied by the pharmaceutical company
To delete reference to the re-usable insulin pen injector OptiPen used for the administration of Insuman 3 ml cartridges as it is no longer produced
4.4 special warnings and precautions for use
Insuman Rapid 100 IU/ml in cartridges is only suitable for subcutaneous injections from a reusable pen. If administration by syringe or intravenous injection is necessary, a vial should be used.
The Insuman Rapid cartridges should only be used with the following pens:
- JuniorSTAR which delivers Insuman Rapid in 0.5 unit dose increments
- OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar and AllStar PRO which all deliver Insuman Rapid in 1 unit dose increments.
These cartridges should not be used with any other reusable pen as the dosing accuracy has only been established with the listed pens (see section 4.2 and 6.6).
Not all of these pens may be marketed in your country.
6.6 Special precautions for disposal and other handling
Insuman Rapid 100 IU/ml in a cartridge
Insulin pen
Insuman Rapid 100 IU/ml in cartridges is only suitable for subcutaneous injections from a reusable pen. If administration by syringe or intravenous injection is necessary, a vial should be used. The Insuman Rapid cartridges are to be used only in conjunction with the pens: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar, AllStar PRO or JuniorSTAR (see section 4.2 and 4.4). Not all of these pens may be marketed in your country.
Updated on 29 May 2018
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.2 - Incompatibilities
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 29 May 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - how to take/use
Updated on 20 March 2018
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 20 March 2018 SPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.1 Therapeutic indications added:-
· Insuman Rapid 100 IU/ml in a cartridge
Section 4.2 Daily doses and timing of administration deleted:-
· Insuman Rapid 100 IU/ml in a cartridge
Section 6.5 deleted:-
· Pack size
Updated on 4 August 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 4 August 2017 PIL
Reasons for updating
- Change to section 3 - dose and frequency
- Change to section 3 - use in children/adolescents
- Change to section 3 - how to take/use
- Change to section 3 - duration of treatment
- Change to section 3 - overdose, missed or forgotten doses
Updated on 27 July 2017 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
IA - B.IV.1.a.1 - To add AllStar PRO reusable pen to the list of pens to be used with the cartridge presentations: the leaflet and carton of the cartridges pack for Insuman Basal, Comb15, Comb25, Infusat and Rapid are updated. The cartons of all the Insumans are also updated to remove ‘Medicinal product subject to medical prescription’ as the ‘POM’ pictogramme applies instead.
IA - B.II.e.5.b - To delete the following presentations for Insuman:
- the 3 mL pre‐filled pen OptiSet of Insuman Rapid, Basal, Comb15, Comb 25, and Comb 50 - solution or suspension for injection 100 IU/mL (EU/1/97/030/065 - 084 and EU/1/97/030/100 - 109)
‐ the 3 mL pre‐filled pen OptiSet of Insuman Comb 30 - suspension for injection 100 IU/mL (EU/1/97/030/178 - 183)
‐ the 3 mL glass cartridge for OptiClik with Insuman Rapid, Basal, Comb15, Comb 25, and Comb 50 - solution or suspension for injection 100 IU/mL (EU/1/97/030/110 - 139)
- the 3 mL glass cartridge for OptiClik with Insuman Comb 30 -suspension for injection 100 IU/mL (EU/1/97/030/184 - 189)
Note: the SPCs for vial, cartridge and pre-filled pens have been combined
IB - C.I.7.a - To delete Insuman Comb 15, suspension for injection 40 IU/mL, in 10 ml vial (EU/1/97/030/041 - 42)
The company took the opportunity to make editorial changes to ET, DE, FI, HU, PL and SL.
Updated on 24 January 2017 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
Updated on 20 December 2013 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.8 updated with the new PV Legislation wording on adverse effect reporting
Updated on 16 December 2013 PIL
Reasons for updating
- Change to, or new use for medicine
- Change to side-effects
- Change to date of revision
Updated on 14 September 2012 PIL
Reasons for updating
- Change to marketing authorisation holder
- Correction of spelling/typing errors
Updated on 20 August 2012 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 11 June 2012 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.2 - Incompatibilities
- Change to section 6.4 - Special precautions for storage
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 4 May 2011 PIL
Reasons for updating
- Change to warnings or special precautions for use
Updated on 28 February 2011 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Changes: Update Section 2 of the PiL: New warning RE: Pioglitazone
Update Product Information in order to add information related to the risk of medication errors
Updated on 3 February 2010 PIL
Reasons for updating
- Improved electronic presentation
Updated on 1 December 2009 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 25 August 2009 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 7 July 2008 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 4 September 2006 SPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may be renewed (B)